Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation. by Couturier, A. et al.
Microglial cells, the main resident sentinel immune cells, 
are located around vessels in the inner part of the healthy 
retina [1-6]. In diabetic retinopathy [7,8], age-related macular 
degeneration (AMD) [9], uveitis [10], and aging [11-13], these 
cells become activated and may migrate in the sub-retinal 
space [13]. The migration and activation of microglia are 
often a non-specific early stress response. Hyperglycemia-
induced glial activation has been suspected to contribute 
to the early development of diabetic retinopathy and is 
associated with electroretinographic alterations before any 
signs of microangiopathy are clinically detectable [14,15]. 
In experimental uveitis or in light-induced retinal damage, 
resident microglia migrate toward the photoreceptor cell layer 
where they generate tumor necrosis factor-alpha (TNF-α) 
and peroxynitrite witnessing nitric oxide (NO) production 
and inducible nitric oxide synthase (iNOS) activation, before 
the circulating macrophages and polymorphonuclear cells 
infiltrate the eye tissue [10]. The cytokines and toxic media-
tors (such as NO) released by activated microglia under these 
conditions are suspected to be neurotoxic to photoreceptor 
cells [16-19] suggesting that activation of microglia may 
contribute to permanent retinal damage. However, retinal 
microglia constitutively secrete interleukin-27 (IL-27), and 
its expression is upregulated during uveitis. IL-27 signaling 
then induces the production of anti-inflammatory molecules 
by photoreceptor cells such as IL-10 and suppressor of cyto-
kine signaling 1 (SOCS1), suggesting that microglia could 
also control the inflammatory response [20]. Microglia, 
depending on its activation state, is a key and early regulator 
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Purpose: To evaluate whether anti-vascular endothelial growth factor (VEGF) neutralizing antibodies injected in the 
vitreous of rat eyes influence retinal microglia and macrophage activation. To dissociate the effect of anti-VEGF on 
microglia and macrophages subsequent to its antiangiogenic effect, we chose a model of acute intraocular inflammation.
Methods: Lewis rats were challenged with systemic lipopolysaccharide (LPS) injection and concomitantly received 5 
µl of rat anti-VEGF-neutralizing antibody (1.5 mg/ml) in the vitreous. Rat immunoglobulin G (IgG) isotype was used 
as the control. The effect of anti-VEGF was evaluated at 24 and 48 h clinically (uveitis scores), biologically (cytokine 
multiplex analysis in ocular media), and histologically (inflammatory cell counts on eye sections). Microglia and mac-
rophages were immunodetected with ionized calcium-binding adaptor molecule 1 (IBA1) staining and counted based on 
their differential shapes (round amoeboid or ramified dendritiform) on sections and flatmounted retinas using confocal 
imaging and automatic quantification. Activation of microglia was also evaluated with inducible nitric oxide synthase 
(iNOS) and IBA1 coimmunostaining. Coimmunolocalization of VEGF receptor 1 and 2 (VEGF-R1 and R2) with IBA1 
was performed on eye sections with or without anti-VEGF treatment.
Results: Neutralizing rat anti-VEGF antibodies significantly decreased ocular VEGF levels but did not decrease the 
endotoxin-induced uveitis (EIU) clinical score or the number of infiltrating cells and cytokines in ocular media (in-
terleukin [IL]-1β, IL-6, tumor necrosis factor [TNF]-α, and monocyte chemoattractant protein [MCP]-1). Eyes treated 
with anti-VEGF showed a significantly decreased number of activated microglia and macrophages in the retina and the 
choroid and decreased iNOS-positive microglia. IBA1-positive cells expressed VEGF-R1 and R2 in the inflamed retina.
Conclusions: Microglia and macrophages expressed VEGF receptors, and intravitreous anti-VEGF influenced the mi-
croglia and macrophage activation state. Taking into account that anti-VEGF drugs are repeatedly injected in the vitreous 
of patients with retinal diseases, part of their effects could result from unsuspected modulation of the microglia activation 
state. This should be further studied in other ocular pathogenic conditions and human pathology.
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in retinal inflammation and a potential modulator of the 
inflammatory response.
The exact molecular events that trigger microglia acti-
vation remain imperfectly understood. Chemokines, and 
CX3CR1 (receptor for CX3C chemokine ligand 1; CX3CL1) 
in particular, have shown to control microglia migration in 
the retina since CX3CR1 knockout (KO) mice show sponta-
neous microglia accumulation in the sub-retinal space and 
subsequent photoreceptor degeneration [9]. In humans, the 
CX3CR1 polymorphism may be associated with wet AMD 
risk [9].
More recently, we have shown that in a non-obese type 2 
diabetic rat, retinal microglia accumulation in the sub-retinal 
space could result from impaired transepithelial migration 
of microglia through intact RPE cells in hyperglycemic 
conditions. In the normal retina, and more intensively with 
aging, transcellular pores have been identified in the RPE, 
which could contribute to microglia trafficking between the 
retina and the choroid [13]. Hyperglycemia could impair this 
physiologic trafficking contributing to sub-retinal activated 
microglia accumulation and subsequent retinal damage.
During endotoxin-induced uveitis (EIU), myeloid cells 
differentially infiltrate tissues of the anterior and posterior 
segments of rat eyes. In the iris, infiltration of monocytes 
is observed as early as 2 h after lipopolysaccharide (LPS) 
injection, followed by massive myeloid cell infiltration, 
mostly polymorphonuclear, at 4–6 h. The number of cells 
with dendritic shape decreases by about 50% at 24 h [21]. In 
the retina, resident macrophages and microglia migrate and 
aggregate around retinal blood vessels at 4 h. At 16 h, when 
uveitis is clinically detectable, a more massive infiltration 
of macrophages with round, pleiomorphic, and dendritiform 
shapes is observed, followed after 72 h and thereafter by a 
predominant dendritiform cells morphologic change all over 
the retina [22]. The chemical depletion of the circulating 
macrophages has given some insight into their pathogenic role 
during EIU. Although significantly decreased cell infiltration 
was observed in the anterior segment, retinal and choroidal 
cell infiltration was not decreased, suggesting that monocyte 
infiltration plays a minor role in retinal inflammation during 
EIU [23]. Interestingly, monocytes and macrophages are now 
viewed as important but complex actors in the pathogenesis 
of age-related macular degeneration [24].
Human monocytes and macrophages express Flt-1 [25], 
and murine brain microglial cells were shown to express in 
vitro, vascular endothelial growth factor (VEGF) receptor 1 
(VEGF-R1, Flt-1) but not VEGF-R [26]. In a model of trau-
matic brain injury, intracerebral injection of VEGF induced 
the invasion of activated microglia in the injured site at day 
5 that persisted up to day 60 [27], suggesting that VEGF 
may be involved in recruiting and activating microglia. In a 
neurodegeneration model induced by intracerebral injection 
of the amyloid-β-peptide, Flt-1 was shown to mediate VEGF-
induced microglial migration and activation, suggesting a 
functional role for Flt-1 in mediating the microglial chemo-
tactic inflammatory response that contributes to pathological 
conditions in Alzheimer disease [28].
Whether anti-VEGF drugs commonly used in ocular 
conditions associated with VEGF increase could modulate 
retinal microglia and macrophage activation has not been 
examined. Anti-VEGF drugs are routinely used in treating 
wet AMD to reduce deleterious consequences of choroidal 
neovascularization [29-31]. In other ocular diseases, anti-
VEGF drugs efficiently reduced macular edema secondary 
to vein occlusion [32] and diabetic retinopathy [33,34]. Inter-
estingly, the chronic use of anti-VEGF for diabetic macular 
edema was shown to exert unexpected beneficial effects on 
the development and severity of diabetic retinopathy, but the 
mechanism of this clinical effect remains unclear [35].
We have hypothesized that anti-VEGF treatments could 
exert direct effects on microglia activation and migration in 
the retina. To explore this hypothesis, we have evaluated the 
effect of a specific rat anti-VEGF antibody, administered 
via an intravitreous route, on migration and activation of rat 
microglia in an acute model of intraocular inflammation, 
EIU. EIU is induced by systemic injection of LPS [36], a 
known activator of retinal microglia [37].
Although anti-VEGF did not influence the severity of 
uveitis, the treatment induced a strong inhibitory effect on 
retinal and choroidal microglia activation. This result suggests 
that anti-VEGF treatments may have indirect unsuspected 
effects on retinal diseases by inhibiting microglia activation.
METHODS
Animal model: All experiments were performed in accor-
dance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research and European Communities 
Council Directive 86/609/EEC. Experiments were submitted 
and approved by the ethic committee of Paris Descartes 
University (number: Ce5/2012/123), The care and use of the 
animals was in compliance with ARVO statement for the Use 
of Animals in Ophthalmic and Vision Research. Accredita-
tion N° of the laboratory: B 75 06 02. Adult female Lewis 
rats (6–8 weeks old; Janvier, Le Genest-Saint-Isle, France) 
were used for in vivo experiments. The rats were anesthe-
tized with intraperitoneal injection of pentobarbital (25 mg/
kg Nembutal; Abbot, Saint-Remy sur Avre, France). Rats 
were killed by a lethal dose of pentobarbital intraperitoneal 
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injection. At least 20 animals per treatment group and 20 
untreated controls or control immunoglobulin G (IgG) were 
used, and the experiments were repeated twice. EIU was 
induced in rats with a single footpad injection of 100 μl sterile 
pyrogen-free saline containing 200 μg LPS from Salmonella 
typhimurium (Sigma-Aldrich, Saint Quentin Fallavier, 
France) [38].
Animals were examined with slit-lamp at 24 h, the 
clinical peak of the disease in our experiments, and at 48 h. 
The intensity of the clinical ocular inflammation was scored 
on a scale from 0 to 5 for each eye, as described previously 
[38]: grade 0: no inflammation; grade 1, minimal iris and 
conjunctival vasodilation but without cells in the anterior 
chamber; grade 2, moderate iris and conjunctival vessel dila-
tion but without evident cells in the anterior chamber; grade 
3, intense iris vessels dilation and fewer than 10 cells per 
slit-lamp field in the anterior chamber; grade 4, more severe 
clinical signs than grade 3, with more than ten cells in the 
anterior chamber with or without the formation of hypopion; 
grade 5, intense inflammatory reaction, fibrin formation in 
the anterior chamber, and total seclusion of the pupil. Clinical 
evaluation was performed in a masked manner.
Treatments: Intravitreous injections were performed using 
microfine (300 μl) syringes with 30G needles under topical 
anesthesia (tetracaine 1%; Sigma-Aldrich). Intravitreous 
injections of 5 μl anti-VEGF (rat VEGF antibody, RnD 
system, Lille, France, at 1.5 mg/ml) or vehicle (PBS; 1X 4.3 
mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4) 
or rat IgG isotype, RnD System, Lille, France at 1.5 mg/ml) 
were performed in the rat eyes at the time of LPS challenge. 
The final vitreous concentration was chosen similar to the 
bevacizumab final concentration commonly used in the clinic 
(1.25 mg in 8 ml, 0.15/ml). Rats were sacrificed by a lethal 
dose of pentobarbital at either 24 or 48 h after injections.
The first experiment was performed with the rat isotype 
IgG antibody, which is the real control to ensure that any 
observed effect is not related to the protein itself but rather 
due to the specific anti-VEGF activity. For this experiment, 
rats were treated with either the vehicle or the IgG isotype 
antibody at the time of LPS injection (five rats/ten eyes per 
group), and they were euthanized at 24 h to quantify the acti-
vated microglia on eye cryosections. Since the isotype IgG 
did not exert an effect, either on inflammation or on microglia 
activation, we then performed all other experiments with the 
vehicle as the control.
Polymorphonuclear cell quantification: Polymorphonuclear 
cells, identified by the shape of their nuclei stained with 
4’,6-diamidino-2-phenyl-indole (DAPI), were quantified on 
histologic sections. The analysis was performed on five eyes 
per experimental group, with six sections per eye at the optic 
nerve head level. Results are expressed as mean ± standard 
deviation (SD). Digitized micrographs were obtained using a 
digital camera (Spot; BFI Optilas, Evry, France).
Sample collection: Aqueous humor and vitreous were 
collected and pooled from each enucleated eye to get enough 
ocular media for multiplex analysis. Ocular media refers to 
the mixed aqueous humor and vitreous from a single eye. 
Ocular fluids were immediately centrifuged. The cell-free 
fractions were collected and frozen at −20 °C before analysis 
with multiplex assay. Neuroretinas were carefully dissected 
from the enucleated eyes, snap frozen, and stored at −80 °C 
until use for RT–PCR analyses. For immunohistochemistry, 
eyeballs were collected and fixed for 1 h at room temperature 
in PBS containing 4% paraformaldehyde before they were 
rinsed overnight in PBS. The next day, the samples were 
embedded and frozen in optimal cutting-temperature (OCT) 
compound (Tissue-Tek; Sakura Finetek, Zoeter-woude, the 
Netherlands) and stored at −80 °C. Cryosections (10 μm 
thick) of eyes were performed at the optic nerve level using 
a cryostat (CM 3050S; Leica, Rueil-Malmaison, France) and 
mounted on slides (Superfrost; Gerhard Menzel, Brausch-
weig, Germany) for immunohistochemical analysis.
Chemokine and cytokine multiplex assay: Intraocular fluids 
were subjected to multiplex bead analysis [38]. This method 
uses microspheres as the solid support for immunoassays 
and allows the titration of a greater number of cytokines 
with increased sensitivity than occurs with enzyme-linked 
immunosorbent assay (ELISA). For each sample, 17 analytes 
were quantified simultaneously using the rat cytokine/
chemokine-17 plex kit (Milliplex Map Kit; Millipore, Saint-
Quentin-en-Yvelines, France) according to the manufacturer’s 
instructions, as follows: chemokines monocyte chemoattrac-
tant protein (MCP)-1/CCL2, MIP-1α/CCL3, RANTES/CCL5, 
IP10/CXCL10 (IFN-inductible protein-10) and GRO/KC; 
proinflammatory mediators IL-1β, IL-8, and TNF-α; Th1/
Th2/Th17 cytokines IL-2 and IFN-γ /IL-4, IL-5, IL-6, Il-10, 
and IL-13/IL17. The assay was performed in a 96-well filter 
plate, and standard curves for each cytokine were generated 
with the rat cytokine standard provided in the kit. All incuba-
tion steps were performed under medium orbital agitation in 
the dark to protect the beads from light. Data acquisition and 
analysis were performed with the manager software version 
4.1 (Bioplex; Bio-Rad) with five logistic parameters for 
standard curves. Detection thresholds for all analytes were 
estimated to be approximately 1 to 10 pg/ml.
Reverse transcription and real-time PCR: Total RNA was 
isolated from neuroretinas from anti-VEGF and vehicle-
injected EIU rat eyes (n = 5 eyes of five rats per group; 
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RNeasy Plus Mini Kit; Qiagen, Courtaboeuf, France). 
First-stand cDNA was synthesized using random primers 
(Invitrogen, Cergy Pontoise, France) and reverse transcrip-
tase (Superscript II; Invitrogen). Transcript levels of nitric 
oxide synthase 2 (NOS2) and TNF-α were analyzed with 
real-time PCR performed in a real-time PCR system (7500 
Real-Time PCR System; Applied Biosystems, Foster City, 
CA) with either SYBR Green (for NOS2) or TaqMan (for 
TNF-α) methodology. RT-qPCR reactions were carried out 
with 100 ng cDNA sample. Non-template control reactions 
were performed for each gene, in order to assure nonspecific 
amplification. Reactions were performed with the following 
thermal profile: 10 min. at 95°C plus 40 cycles of 15 seconds 
at 95°C and 1 min. at 60°C. Real-time PCR results were 
analyzed with SDS 2.1 software (Applied Biosystems) and 
quantification were calculated on the basis of threshold cycle 
(CT) for the target gene and the reference gene 18S according 
to the following formula: 2 Δ(CT(GADPH) - CT(Target)).The 
18S was used as an internal control. The delta cycle threshold 
calculation was used for relative quantification of the results.
Immunofluorescence: Microglial cells were visualized with 
immunofluorescence, using rabbit polyclonal anti-ionized 
calcium binding adaptor molecule 1 (anti-IBA1; 1:400, 
Wako, Richmond, VA), a specific marker for microglia and 
macrophages [39]. To evaluate microglial cell activation, 
NOS2 expression was visualized using a mouse monoclonal 
anti-NOS2 (1:100; Santa Cruz Biotechnology, Heidelberg, 
Germany). Expression of VEGF-R1 and VEGF-R2 was 
evaluated with coimmunostaining with IBA1.
Briefly, after permeabilization with 0.1% Triton X-100 
in PBS for 30 min, specimens were rinsed and saturated for 
30 min with 5% goat serum in PBS. They were incubated 
overnight at 4 °C with the primary antibodies. After washing, 
sections were incubated for 1 h at room temperature with 
a secondary Alexa Fluor 488 (green)-conjugated goat anti-
rabbit monoclonal antibody and a secondary Alexa Fluor 
594 (red)-conjugated goat anti-mouse monoclonal antibody, 
each at dilution 1:200 (Invitrogen). For each step, antibodies 
were diluted in PBS-1% goat serum. After the nuclei were 
stained with DAPI (1:5,000; Sigma-Aldrich), the sections 
were mounted with gel mount and were observed with a 
fluorescence laser scanning microscope (Olympus BX51, 
Rungis, France).
Quantification of activated ionized calcium-binding adaptor 
molecule 1–stained cells: To quantify microglial activation 
and migration, IBA1 round amoeboid cells were counted on 
six retina and choroid 7 µm sections at the optic nerve level 
(and on five eyes per treatment group). Cell number was 
expressed as the mean ± standard deviation (SD) of the total 
cells per section.
Retinal f latmounting: Eyes were fixed for 15 min in 4% 
paraformaldehyde (Ladd Research Industries, Inland Europe, 
Conflans-sur-Lanterne, France). After being washed, the 
retinas were isolated, cut into four orthogonal incisions, and 
postfixed with acetone 100% at −20 °C for 15 min. They were 
then rehydrated with PBS containing 1% Triton X-100, and 
incubated with the rabbit anti-IBA1 antibody (1:400) at room 
temperature under stirring overnight. After being washed 
with PBS, the Alexa Fluor 488-conjugated goat anti-rabbit 
IgG (1:200; Molecular Probes, Leiden, the Netherlands) was 
applied for 1 h. The retinas were flatmounted using gel mount 
with the vitreous side up. Images were taken using a fluores-
cence laser scanning microscope (Olympus BX51, Rungis, 
France) and a confocal laser scanning microscope (Zeiss 
LSM 710; Carl Zeiss MicroImaging, Oberkochen, Germany). 
Confocal microscopic images spanning the full thickness of 
the retina were performed by scanning at 1 µm increments 
(objective 20X lens). The total IBA1 immunostained area was 
quantified on flatmounted images, using automatic measure-
ments of the IBA1 surface (ImageJ). A specific macro was 
built to distinguish between the round IBA1 staining area and 
the total IBA1 staining area. To confirm that this program 
adequately distinguished round amoeboid IBA1-positive 
cells, we correlated automated drawing of round cells and 
amoeboid and IBA1-positive cells to manual counts on 
two areas (of 1 mm2) of five retinas (by two independent 
observers). The correlation coefficient was 98%. This method 
was therefore used to quantify IBA1 staining on eight regions 
(of 1 mm2) from the different quadrants of the retina (two per 
quadrants).
Statistical analysis: Data are expressed as mean ± standard 
error of the mean (SEM). Statistical analysis was conducted 
using a software program for predictive analytics (GraphPad 
Prism 5; GraphPad Software, San Diego, CA). The Mann–
Whitney test was used when two groups were compared. 
Values of p<0.05 were considered significant.
RESULTS
Vascular endothelial growth factor neutralization does not 
exert an anti-inflammatory effect on endotoxin-induced 
uveitis: Intravitreous injection of rat anti-VEGF antibody at 
the time of the LPS challenge did not influence the clinical 
uveitis score at 24 h (2.6±0.2) or at 48 h (1.7±0.1) compared to 
vehicle injection (2.8±0.1 and 1.80±0.4 at 24 and 48 h, respec-
tively, n = 5 rats per group, p>0.05; Figure 1A). Rat anti-VEGF 
significantly reduced ocular VEGF levels at 24 h from 16.7±5 
pg/ml to 3.36±1.3 pg/ml in rat ocular media (n = 5 rats per 
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group, p = 0.0436; Figure 1B) validating its expected biologic 
effect, but did not reduce the severity or duration of EIU in 
rats. Rat isotype IgG did not exert an anti-inflammatory 
effect and did not reduce ocular VEGF (data not shown). In 
agreement with clinical scoring, cytokines, measured in the 
ocular media of rats at either 24 or 48 h after LPS injection 
using multiplex, did not vary significantly in the group of rats 
treated with anti-VEGF compared to the vehicle-treated rats. 
In particular, the IL-1β level was measured at 130.9±48.99 pg/
ml in the anti-VEGF group versus 99.54±11.34 pg/ml in the 
vehicle group, p = 0.5501; IL-6 3587±493.9 pg/ml in the anti-
VEGF group versus 4879±560.1 pg/ml in the vehicle group, 
p = 0.1266; TNF-α was 21.46±4.35 pg/ml in the anti-VEGF 
group versus 27.36±2.45 pg/ml in the vehicle group, p = 
0.3090; MCP-1 was 9854±1239 pg/ml in the anti-VEGF group 
versus 10,596±374.7 pg/ml in the vehicle group, p = 0.6226). 
At 48 h, ocular cytokines decreased similarly in both groups 
(data not shown; IL-1β was 23.43±7.24 pg/ml in the anti-
VEGF group versus 28.63±18.50 pg/ml in the vehicle group, 
p = 0.8003; IL-6 171.8±51.70 pg/ml in the anti-VEGF group 
versus 410.3±107.2 pg/ml in the vehicle group, p = 0.0685; 
TNF-α was 6.87±1.59 pg/ml in the anti-VEGF group versus 
7.50±0.69 pg/ml in the vehicle group, p = 0.7273; MCP-1 was 
2853±667.2 pg/ml in the anti-VEGF group versus 3899±706.8 
pg/ml in the vehicle group, p = 0.3132).
In agreement with the cytokine levels and clinical 
scoring, at 24 h, the number of polymorphonuclear cells 
infiltrating the ocular tissues did not differ significantly 
in eyes treated with vehicle (14.9±2.1 cells/section, n = 5), 
compared with eyes treated with anti-VEGF (13.3±3.5 cells/
section, n = 5, p>0.05; Figure 1C). All together, these results 
show that neutralizing VEGF does not exert an anti-inflam-
matory effect on EIU.
Vascular endothelial growth factor neutralization reduces the 
number of round activated microglia in endotoxin-induced 
uveitis: Activation of microglia induces modification of its 
shape from ramified multidirectional extensions to polarized 
dendrites and then to round amoeboid cells (Figure 2A,D 
inset). The number of activated round amoeboid microglia did 
not vary significantly in eyes treated with the rat IgG isotype 
antibody compared to the vehicle-treated eyes (n = 5 rats per 
group, p>0.05; Figure 2H). However, in the eyes treated with 
anti-VEGF at 24 h compared to the vehicle-injected eyes, the 
number of round amoeboid IBA1-positive cells was signifi-
cantly decreased in the inner retina (18.42±1.35 cells/section 
in the inner retina compared to 39±0.5 cells/section, n=5 rats 
per group, p<0.0001), the outer retina (2.2±0.5 cells/section as 
compared to 9±1.8 cells/section, n = 5 rats per group, p<0.001), 
and the choroid (41±2.5 cells/section compared to 56±6 cells/
section, n = 5 rats per group, p<0.05; Figure 2A-G). At 48 h, 
although numerous activated cells were still present in the 
retina and the choroid of rats with EIU, the IBA1-positive 
cells could hardly be identified in the anti-VEGF-treated rats 
(not shown). The morphology of IBA1-positive cells was also 
Figure 1. Clinical and biological effects of anti-VEGF on EIU in rats. A: Clinical scoring of endotoxin-induced uveitis (EIU; n = 5 rats per 
group, p>0.05). B: vascular endothelial growth factor (VEGF) ocular levels (pg/ml) at 24 h (n = 5 rats per group, p = 0.0436). C: Polymor-
phonuclear cell infiltration in the anterior segment (AS) and in the posterior segment (PS) of rats (five sections/ eye, five eyes per group). 
D: Ocular levels of interleukin (IL)1-β (πγ/μλ; n = 5, p = 0.55), E: IL-6 (pg/ml; n = 5, p = 0.068). F: Monocyte chemoattractant protein-1 
(MCP-1; pg/ml; n = 5, p = 0.3132). G: Tumor necrosis factor (TNF)-α (πγ/μλ; n = 5, p = 0.7273).
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modified by anti-VEGF treatment in the iris and ciliary body 
(not shown) and the choroid (Figure 2D-G), where numerous 
round cells were observed in the EIU-vehicle-injected eyes 
compared to the ramified, dendritic IBA1-positive cells in 
the anti-VEGF-injected eyes. Because quantifying cells on 
sections may not represent cellular events that occur all over 
the retina, we also counted IBA1-positive cells on the entire 
flatmounted retina.
On the flatmounted retinas, numerous round amoeboid 
microglia were observed in the vehicle-injected EIU rats 
(Figure 3A–C, arrows), while more ramified cells were 
observed after anti-VEGF treatment (Figure 3B-D). To count 
the total number of microglia in the inner neuroretina and 
the relative number of round and ramified IBA1-positive 
cells, the surface of the fluorescently stained IBA1-positive 
cells was analyzed automatically after the different microglia 
shapes were captured on the flatmounted retina as illustrated 
in Figure 3C,D. This automated quantification showed that 
although no significant difference was observed in the 
total surface of IBA1 staining between the anti-VEGF and 
Figure 2. Ionized calcium-binding adaptor molecule 1 immunostaining of microglia and macrophages in endotoxin-induced uveitis at 24 h 
after lipopolysaccharide injection A: Retina section after vehicle intravitreal injection; in green ionized calcium-binding adaptor molecule 
1 (IBA1) staining and in blue nuclei are stained with 4’,6-diamidino-2-phenyl-indole (DAPI). Arrowheads indicates round IBA1-positive 
cells, magnified in the inset. Bar = 50 µm, GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. B: Retina section 
after anti-vascular endothelial growth factor (VEGF) intravitreal injection. IBA1-positive cells (in green) are ramified and elongated in the 
inner retina as magnified in the inset. Nuclei are stained in blue with DAPI. Bar = 50 µm, GCL = ganglion cell layer, INL = inner nuclear 
layer, ONL = outer nuclear layer. D–F: Choroid section after vehicle intravitreal injection stained with IBA1 (D) and DAPI (F), showing 
round amoeboid cells (magnified in the inset). Bar = 50 µm, RPE = retinal pigment epithelial cells. E–G: Choroid section after anti-VEGF 
intravitreal injection stained with IBA1 (E) and DAPI (G), showing round elongated ramified cells (magnified in the inset). Bar = 50 µm, 
RPE = retinal pigment epithelial cells. C and H: Quantification of round IBA1-positive cells in the inner and outer retina and in the choroid 
of rat eyes with EIU at 24 h, injected either with vehicle or with anti-VEGF antibody (C) or with control rat isotype immunoglobulin G 
(IgG) antibodies (H) *p<0.05, ***p<0.0001.
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vehicle-treated eyes (n = 10 retinas per group, p>0.05), the 
area of fluorescence resulting from round IBA1 immunola-
beled cells was significantly decreased after anti-VEGF treat-
ment compared to the vehicle-treated eyes (n = 10 retinas per 
group, p<0.05; Figure 3E,F). NOS2 is expressed in activated 
macrophages and microglia and is a marker of the activation 
state [13,38]. As shown in Figure 4, double-stained IBA1/
NOS2 positive round cells were identified in the retinas of 
eyes with EIU treated with vehicle (Figure 4A–C), but none 
were found in the anti-VEGF-treated eyes (Figure 4D-F). 
NOS2 expression was also decreased at the mRNA levels 
in the anti-VEGF-treated retinas compared to the vehicle-
treated retinas (Figure 4G). TNF-α expression by microglia 
is also a marker of its activation, but TNF-α expression was 
not significantly reduced in the whole neuroretina of eyes 
treated with anti-VEGF compared to controls even if a trend 
was observed (data not shown).
Figure 3. Ionized calcium-binding adaptor molecule 1 immunostaining on flatmounted retinas. A–B: Example of flatmounted retinas from 
rat eyes with endotoxin-induced uveitis (EIU) injected with vehicle (A) or with antivascular endothelial growth factor (VEGF) antibodies 
(B); Bar = 50 µm. Arrowhead show round reactive ionized calcium-binding adaptor molecule 1 (IBA1)-positive cells. C–D: Extraction of 
cell contours used for automatic labeling of IBA1 staining. E-F: Quantification of round and total IBA-1 positive cells on flat-mounted retina 
from EIU control and anti-VEGF treated eyes. Bar = 50 µm.
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Vascular endothelial growth factor receptor expression 
in retinal microglia: At 24 h after LPS injection, VEGF 
receptor expression was evaluated in microglial cells with 
coimmunostaining of VEGF-R1 or -R2 and IBA1. A subset 
of IBA1-positive cells expressed VEGF-R1, particularly 
the round activated ones (Figure 5A-C and inset). In eyes 
treated with anti-VEGF, VEGF-R1 remained expressed in a 
subset of IBA1-positive cells (Figure 5D-F). VEGF-R2 was 
expressed in sparse perivascular IBA1-positive cells (Figure 
6A-C and inset). In the anti-VEGF-treated eyes, the expres-
sion of VEGF-R2 decreased in deactivated macrophages and 
microglia (Figure 6D-F).
DISCUSSION
Anti-VEGF drugs used in treating retinal diseases aim at 
controlling angiogenic processes or vascular leakage that are 
at least partly VEGF-driven [40]. However, the mechanisms 
of action of anti-VEGF drugs on various retinal diseases 
are not fully understood. Sub-clinical inflammation with 
microglial or macrophage activation has been suspected to 
contribute to retinal pathogenesis in diabetic retinopathy and 
age-related macular degeneration [11,24], but the effect of 
anti-VEGF treatment on retinal microglia and macrophages 
has not been analyzed independently from an angiogenic 
context although anti-VEGF drugs were approved for 
macular edema not related to neovascularization. Impor-
tantly, macrophages express VEGFR-1 (Flt-1), and the use of 
Figure 4. Inducible nitric oxide synthase expression: immunohistochemistry and RT–PCR inducible nitric oxide synthase and ionized 
calcium-binding adaptor molecule 1 coimmunostaining on retinal sections of rats with endotoxin-induced uveitis injected with vehicle 
(A–C) or with antivascular endothelial growth factor (D–F). A and D: Ionized calcium-binding adaptor molecule 1 (IBA1) cells are labeled 
in green, iNOS is labeled in red and nuclei are stained in blue with 4’,6-diamidino-2-phenyl-indole (DAPI). B and E: IBA1 cells labeled 
in green. C and F: Inducible nitric oxide synthase (iNOS) labeled in red. GCL = ganglion cell layer, INL = inner nuclear layer, ONL = 
outer nuclear layer, RPE = retinal pigment epithelial cells, Chor: choroid. Bar = 50 µm. Insets are increased magnifications (5X) of regions 
delimited by squares. G: iNOS mRNA expression on retinal extracts from vehicle and antivascular endothelial growth factor (anti-VEGF) 
rat eyes; n = 5 per groups * p<0.05).
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Flt-1-deficient mice demonstrated that in rheumatoid arthritis 
models, VEGF induced macrophage activation through Flt-
1-dependent signaling [41,42]. In the brain, VEGF-induced 
migration and proliferation of microglia were also shown to 
result from Flt-1 activation [26], which mediated microglial 
responses to the amyloid peptide, suggesting its contribution 
in Alzheimer disease [28].
In the rat retina, we found that microglia and macro-
phages express Flt-1 (VEGF-R1) in inflammatory conditions 
in vehicle- and anti-VEGF-treated eyes. However, not all 
IBA1-positive cells expressed VEGF-R1 suggesting that 
potentially only a subset of cells is directly VEGF-sensitive. 
Interestingly, in eyes with EIU, reactive round microglia cells 
seemed to overexpress VEGF-R1 compared to the inactivated 
dendritic ones and expressed VEGF-R2. This overexpres-
sion of Flt-1 was found in vitro in activated monocytes [43]. 
Moreover, in a rat model of spinal cord injury, upregulation of 
VEGF-R1 and VEGF-R2 mRNA occurred in microglia and 
macrophages that infiltrated the lesion site early, suggesting 
that in activated conditions both VEGF receptors could be 
expressed [44].
Macrophages and microglia express VEGF receptors, 
and have been recognized in the pathogenesis of retinal 
diseases treated with anti-VEGF. Therefore, we studied the 
effect of anti-VEGF in an acute model of ocular inflammation 
in which microglial migration and activation have been previ-
ously characterized [45]. This inflammatory non-angiogenic 
model was chosen to distinguish anti-VEGF effects not 
Figure 5. VEGF-R1 and IBA1 co-immunostaining on retinal sections retinal sections of EIU rats injected with vehicle (A–C) or anti-VEGF 
(D–F). GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer, RPE = retinal pigment epithelial cells, Chor = 
choroid. Insets are increased magnification (5X) of regions delimited by squares. Bar = 50 µm.
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related to inhibition of angiogenesis. Whereas treatment 
with specific rat anti-VEGF antibodies reduces ocular VEGF 
levels, it does not significantly reduce inflammation clinically 
and biologically. Indeed, no significant decrease in the major 
cytokines involved in EIU was measured in the ocular media, 
and no significant decrease in infiltrating polymorphonuclear 
was observed after anti-VEGF treatment. However, reducing 
VEGF by neutralizing anti-VEGF antibodies decreased the 
activation state of the microglia and macrophages in the retina 
and the choroid, as shown by the decreased round amoeboid 
IBA1-positive cells and the decreased production of NOS2 by 
those cells. These effects were specific since the rat isotype 
IgG had no effect, demonstrating that anti-VEGF has direct 
modulating effects on the activation state of microglia and 
macrophages.
Previous work from our group demonstrated that macro-
phage and microglia depletion by liposomes containing 
dichloromethylene-diphosphonate decreased clinical signs 
of EIU but did not decrease cellular retinal infiltration [23]. 
Several reasons can explain this discrepancy. First, the route 
of injection of anti-VEGF antibody in the vitreous might not 
be optimal in this model of ocular inflammation that affects 
the anterior segment of the eye. Moreover, placental growth 
factor (PGF) that activated Flt-1 [46] is not neutralized by 
anti-VEGF antibody. This could explain that microglia and 
macrophages were partially deactivated as shown by the 
non-significant downregulation of TNF-α in the retina in the 
treated eyes. Another explanation could be that only a subset 
of microglia and macrophages express VEGF receptors 
suggesting that other factors could modulate their activation 
state. Moreover, deactivation of macrophages and microglia 
is not directly comparable to depletion of macrophages 
and microglia. The balance of pro- and anti-inflammatory 
mediators produced by macrophages and microglia probably 
regulates ocular inflammation in a more complex manner 
[47,48]. Finally, the local administration of anti-VEGF prob-
ably does not act on circulating monocytes since its systemic 
passage is low.
In our experiments, we cannot exclude that anti-VEGF 
also acted on infiltrating myeloid cells that are also labeled 
Figure 6. VEGF-R2 and IBA1 coimmunostaining on retinal sections retinal sections of EIU rats injected with vehicle (A–C) or anti-VEGF 
(D–F). GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer, RPE = retinal pigment epithelial cells, Chor = 
choroid. Insets are increased magnification (5X) of regions delimited by squares. Bar = 50 µm.
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by IBA1. However, the systemic depletion of circulating 
macrophages did not decrease the retinal cellular infiltra-
tion suggesting that circulating monoctyes and macrophages 
poorly contribute to inflammation in the posterior segment 
[23].
No animal model recapitulates all features of human 
diseases, but the fact that in a specific model of acute inflam-
mation, anti-VEGF exerts direct effects on the activation of 
microglia and macrophages in the retina and the choroid 
suggests that similar effects could intervene in more complex 
retinal diseases where sub-clinical inflammation and microg-
lial activation are suspected to be pathogenic. Clinical studies 
suggested that long-term anti-VEGF treatment for diabetic 
macular edema had an unexpected effect on the diabetic reti-
nopathy severity [35]. Microglia deactivation by anti-VEGF 
could be a mechanism that mediates this beneficial effect. 
Novel anti-VEGF drugs such as aflibercept that neutralize 
VEGF and PGF might have potentiated activity on microglia 
activation. However, whether VEGF-induced microglia acti-
vation could have beneficial effects on clearance of retinal 
debris as shown for alveolar macrophages [49] remains to be 
evaluated, and whether full inhibition of microglia activation 
would be more beneficial in the retina remains unclear.
In conclusion, anti-VEGF drugs may exert significant 
unsuspected effects on retinal and choroidal microglia and 
macrophages that play important and complex roles in the 
pathogenesis of retinal diseases. Further studies should 
evaluate these effects in different ocular models of retinal 
diseases.
REFERENCES
1. Hickey WF, Kimura H. Perivascular microglial cells of the 
CNS are bone marrow-derived and present antigen in vivo. 
Science  1988; 239:290-2. [PMID: 3276004].
2. Perry VH, Gordon S. Macrophages and microglia in the 
nervous system.  Trends Neurosci  1988; 11:273-7. [PMID: 
2465626].
3. Streit WJ, Graeber MB, Kreutzberg GW. Functional plasticity 
of microglia: a review.  Glia  1988; 1:301-7. [PMID: 2976393].
4. Lassmann H, Schmied M, Vass K, Hickey WF. Bone marrow 
derived elements and resident microglia in brain inflamma-
tion.  Glia  1993; 7:19-24. [PMID: 7678581].
5. Ling EA, Wong WC. The origin and nature of ramified and 
amoeboid microglia: a historical review and current concepts. 
Glia  1993; 7:9-18. [PMID: 8423067].
6. Ling EA. Monocytic origin of ramified microglia in the corpus 
callosum in postnatal rat.  Neuropathol Appl Neurobiol  1994; 
20:182-3. [PMID: 8072651].
7. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response 
in the retina of streptozotocin-induced diabetic rats.  Vis 
Neurosci  2000; 17:463-71. [PMID: 10910112].
8. Zeng HY, Green WR, Tso MOM. Microglial activation in 
human diabetic retinopathy.  Arch Ophthalmol  2008; 
126:227-32. [PMID: 18268214].
9. Combadière C, Feumi C, Raoul W, Keller N, Rodéro M, 
Pézard A, Lavalette S, Houssier M, Jonet L, Picard E, Debré 
P, Sirinyan M, Deterre P, Ferroukhi T, Cohen SY, Chauvaud 
D, Jeanny JC, Chemtob S, Behar-Cohen F, Sennlaub F. 
CX3CR1-dependent subretinal microglia cell accumulation 
is associated with cardinal features of age-related macular 
degeneration.  J Clin Invest  2007; 117:2920-8. [PMID: 
17909628].
10. Rao NA, Kimoto T, Zamir E, Giri R, Wang R, Ito S, Parara-
jasegaram G, Read RW, Wu GS. Pathogenic role of retinal 
microglia in experimental uveoretinitis.  Invest Ophthalmol 
Vis Sci  2003; 44:22-31. [PMID: 12506051].
11. Xu H, Chen M, Forrester JV. Para-inflammation in the aging 
retina.  Prog Retin Eye Res  2009; 28:348-68. [PMID: 
19560552].
12. Xu H, Chen M, Manivannan A, Lois N, Forrester JV. Age-
dependent accumulation of lipofuscin in perivascular and 
subretinal microglia in experimental mice.  Aging Cell  2008; 
7:58-68. [PMID: 17988243].
13. Omri S, Behar-Cohen F, de Kozak Y, Sennlaub F, Verissimo 
LM, Jonet L, Savoldelli M, Omri B, Crisanti P. Microglia/
macrophages migrate through retinal epithelium barrier by 
a transcellular route in diabetic retinopathy: role of PKCζ in 
the Goto Kakizaki rat model.  Am J Pathol  2011; 179:942-53. 
[PMID: 21712024].
14. Gaucher D, Chiappore JA, Pâques M, Simonutti M, Boitard 
C, Sahel JA, Massin P, Picaud S. Microglial changes occur 
without neural cell death in diabetic retinopathy.  Vision Res 
2007; 47:612-23. [PMID: 17267004].
15. Kern TS. Contributions of inflammatory processes to the 
development of the early stages of diabetic retinopathy.  Exp 
Diabetes Res  2007; 2007:95103-[PMID: 18274606].
16. Xu H, Chen M, Mayer EJ, Forrester JV, Dick AD. Turnover of 
resident retinal microglia in the normal adult mouse.  Glia 
2007; 55:1189-98. [PMID: 17600341].
17. Ma W, Zhao L, Fontainhas AM, Fariss RN, Wong WT. 
Microglia in the mouse retina alter the structure and func-
tion of retinal pigmented epithelial cells: a potential cellular 
interaction relevant to AMD.  PLoS ONE  2009; 4:e7945-
[PMID: 19936204].
18. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, 
Levison SW. Minocycline reduces proinflammatory cytokine 
expression, microglial activation, and caspase-3 activation 
in a rodent model of diabetic retinopathy.  Diabetes  2005; 
54:1559-65. [PMID: 15855346].
19. Zhang M, Xu G, Liu W, Ni Y, Zhou W. Role of fractalkine/
CX3CR1 interaction in light-induced photoreceptor 
Molecular Vision 2014; 20:908-920 <http://www.molvis.org/molvis/v20/908> © 2014 Molecular Vision 
919
degeneration through regulating retinal microglial activa-
tion and migration.  PLoS ONE  2012; 7:e35446-[PMID: 
22536384].
20. Lee YS, Amadi-Obi A, Yu C-R, Egwuagu CE. Retinal cells 
suppress intraocular inflammation (uveitis) through produc-
tion of interleukin-27 and interleukin-10.  Immunology  2011; 
132:492-502. [PMID: 21294722].
21. McMenamin PG, Crewe J. Endotoxin-induced uveitis. Kinetics 
and phenotype of the inflammatory cell infiltrate and the 
response of the resident tissue macrophages and dendritic 
cells in the iris and ciliary body.  Invest Ophthalmol Vis Sci 
1995; 36:1949-59. [PMID: 7657537].
22. Yang P, de Vos AF, Kijlstra A. Macrophages in the retina of 
normal Lewis rats and their dynamics after injection of lipo-
polysaccharide.  Invest Ophthalmol Vis Sci  1996; 37:77-85. 
[PMID: 8550337].
23. Pouvreau I, Zech JC, Thillaye-Goldenberg B, Naud MC, Van 
Rooijen N, de Kozak Y. Effect of macrophage depletion by 
liposomes containing dichloromethylene-diphosphonate on 
endotoxin-induced uveitis.  J Neuroimmunol  1998; 86:171-
81. [PMID: 9663563].
24. Grunin M, Hagbi-Levi S, Chowers I. The role of monocytes 
and macrophages in age-related macular degeneration.  Adv 
Exp Med Biol  2014; 801:199-205. [PMID: 24664699].
25. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, 
Shibuya M. Flt-1, vascular endothelial growth factor receptor 
1, is a novel cell surface marker for the lineage of monocyte-
macrophages in humans.  Blood  2001; 97:785-91. [PMID: 
11157498].
26. Forstreuter F, Lucius R, Mentlein R. Vascular endothelial 
growth factor induces chemotaxis and proliferation of 
microglial cells.  J Neuroimmunol  2002; 132:93-8. [PMID: 
12417438].
27. Norazit A, Nguyen MN, Dickson CG, Tuxworth G, Goss B, 
Mackay-Sim A, Meedeniya AC. Vascular endothelial growth 
factor and platelet derived growth factor modulates the glial 
response to a cortical stab injury.  Neuroscience  2011; 
192:652-60. [PMID: 21704679].
28. Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. Microglial 
VEGF receptor response is an integral chemotactic compo-
nent in Alzheimer’s disease pathology.  J Neurosci  2009; 
29:3-13. [PMID: 19129379].
29. Dhoot DS, Kaiser PK. Ranibizumab for age-related macular 
degeneration.  Expert Opin Biol Ther  2012; 12:371-81. 
[PMID: 22309606].
30. Ohr M, Kaiser PK. Aflibercept in wet age-related macular 
degeneration: a perspective review.  Ther Adv Chronic Dis 
2012; 3:153-61. [PMID: 23342231].
31. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Afliber-
cept for age-related macular degeneration: a game-changer or 
quiet addition?  Am J Ophthalmol  2012; 154:222-6. [PMID: 
22813448].
32. Campochiaro PA. Anti-vascular endothelial growth factor 
treatment for retinal vein occlusions.  Ophthalmologica 
2012; 227:Suppl 130-5. [PMID: 22517123].
33. Ho AC, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS, 
Recchia FM. Anti-vascular endothelial growth factor phar-
macotherapy for diabetic macular edema: a report by the 
American Academy of Ophthalmology.  Ophthalmology 
2012; 119:2179-88. [PMID: 22917890].
34. Zechmeister-Koss I, Huic M. Vascular endothelial growth 
factor inhibitors (anti-VEGF) in the management of diabetic 
macular oedema: a systematic review.  Br J Ophthalmol 
2012; 96:167-78. [PMID: 22133986].
35. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-
term effects of ranibizumab on diabetic retinopathy severity 
and progression.  Arch Ophthalmol  2012; 130:1145-52. .
36. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endo-
toxin-induced uveitis in rats as a model for human disease. 
Nature  1980; 286:611-3. [PMID: 7402339].
37. Wang AL, Yu AC, Lau LT, Lee C. Wu le M, Zhu X, Tso MO. 
Minocycline inhibits LPS-induced retinal microglia activa-
tion.  Neurochem Int  2005; 47:152-8. .
38. Bousquet E, Zhao M, Ly A, Leroux Les Jardins G, Goldenberg 
B, Naud MC, Jonet L, Besson-Lescure B, Jaisser F, Farman 
N, De Kozak Y, Behar-Cohen F. The aldosterone-mineralo-
corticoid receptor pathway exerts anti-inflammatory effects 
in endotoxin-induced uveitis.  PLoS ONE  2012; 7:e49036-.
39. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macro-
phage-specific protein Iba1 binds to fimbrin and enhances 
its actin-bundling activity.  J Neurochem  2004; 88:844-56. 
Available at[PMID: 14756805].
40. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular 
endothelial growth factor a in intraocular vascular disease. 
Ophthalmology  2013; 120:106-14. [PMID: 23031671].
41. Shibuya M. Vascular endothelial growth factor and its receptor 
system: physiological functions in angiogenesis and patho-
logical roles in various diseases.  J Biochem  2013; 153:13-9. 
[PMID: 23172303].
42. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura 
K, Iwakura Y, Shibuya M. Signaling of vascular endothelial 
growth factor receptor-1 tyrosine kinase promotes rheuma-
toid arthritis through activation of monocytes/macrophages. 
Blood  2006; 108:1849-56. .
43. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, 
Marmé D. Migration of human monocytes in response to 
vascular endothelial growth factor (VEGF) is mediated via 
the VEGF receptor flt-1.  Blood  1996; 87:3336-43. .
44. Choi JS, Kim HY, Cha JH, Choi JY, Park SI, Jeong CH, Jeun 
SS, Lee MY. Upregulation of vascular endothelial growth 
factor receptors Flt-1 and Flk-1 following acute spinal cord 
contusion in rats.  J Histochem Cytochem  2007; 55:821-30. .
45. Lemaitre C, Thillaye-Goldenberg B, Naud MC, De Kozak 
Y. The effects of intraocular injection of interleukin-13 on 
endotoxin-induced uveitis in rats.  Invest Ophthalmol Vis Sci 
2001; 42:2022-30. [PMID: 11481267].
Molecular Vision 2014; 20:908-920 <http://www.molvis.org/molvis/v20/908> © 2014 Molecular Vision 
920
46. Autiero M, Waltenberger J, Communi D, Kranz A, Moons 
L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, 
Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-
Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, 
Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert 
JM, Communi D, Shibuya M, Collen D, Conway EM, Carme-
liet P. Role of PlGF in the intra- and intermolecular cross talk 
between the VEGF receptors Flt1 and Flk1.  Nat Med  2003; 
9:936-43. .
47. Broderick C, Duncan L, Taylor N, Dick AD. IFN-gamma 
and LPS-mediated IL-10-dependent suppression of retinal 
microglial activation.  Invest Ophthalmol Vis Sci  2000; 
41:2613-22. [PMID: 10937574].
48. Kearns MT, Dalal S, Horstmann SA, Richens TR, Tanaka T, 
Doe JM, Boe DM, Voelkel NF, Taraseviciene-Stewart L, 
Janssen WJ, Lee CG, Elias JA, Bratton D, Tuder RM, Henson 
PM, Vandivier RW. Vascular endothelial growth factor 
enhances macrophage clearance of apoptotic cells.  Am J 
Physiol Lung Cell Mol Physiol  2012; 302:L711-8. .
49. Chen L, Yang P, Kijlstra A. Distribution, markers, and func-
tions of retinal microglia.  Ocul Immunol Inflamm  2002; 
10:27-39. [PMID: 12461701].
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. 
The print version of this article was created on 23 June 2014. This reflects all typographical corrections and errata to the article 
through that date. Details of any changes may be found in the online version of the article.
